[Skip to Content]
[Skip to Content Landing]
Views 256
Citations 0
Comment & Response
March 5, 2020

Evaluation of POLE/POLD1 Variants as Potential Biomarkers for Immune Checkpoint Inhibitor Treatment Outcomes—Reply

Author Affiliations
  • 1State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China
JAMA Oncol. Published online March 5, 2020. doi:10.1001/jamaoncol.2020.0068

In Reply We thank Golmard et al and Rousseau et al for their comments on our Research Letter.1 The major concern was the inclusion of all the nonsynonymous variants in the analysis. We agree that not all POLE/POLD1 variants can lead to an ultramutated phenotype. A previous study2 has shown that some POLE/POLD1 variants outside of the exonuclease domain are also capable of damaging their proofreading function and leading to an ultramutated phenotype. Thus, defining pathogenic variants according to the variant location is not accurate enough. In our further analysis, the results show that patients with variants outside of the exonuclease domain also had a better prognosis than patients with wild-type variants in the immune checkpoint inhibitor (ICI) treatment cohort. Variants of POLE/POLD1 can serve as a biomarker in immunotherapy regardless of whether they are located in the exonuclease domain.

Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words